PeptideDB

JGB-1741 (ILS-JGB-1741) 1256375-38-8

JGB-1741 (ILS-JGB-1741) 1256375-38-8

CAS No.: 1256375-38-8

JGB1741 (ILS-JGB-1741) is a novel SIRT1 activity inhibitor with an IC50 of ~15 μM. JGB1741 is an IC50 >100 μM weak inh
Sales Email:peptidedb@qq.com

This product is for research use only, not for human use. We do not sell to patients.

JGB1741 (ILS-JGB-1741) is a novel SIRT1 activity inhibitor with an IC50 of ~15 μM. JGB1741 is an IC50 >100 μM weak inhibitor of SIRT2 and SIRT3. JGB1741 modulates the Bax/Bcl2 ratio, cytochrome c release, and PARP cleavage in addition to raising the levels of acetylated p53, which causes p53-mediated apoptosis. JGB1741 may be useful in studies on breast cancer.

Physicochemical Properties


Molecular Formula C27H24N2O2S
Molecular Weight 440.56
Exact Mass 440.155
CAS # 1256375-38-8
PubChem CID 136232142
Appearance Light yellow to yellow solid powder
Density 1.3±0.1 g/cm3
Boiling Point 700.2±60.0 °C at 760 mmHg
Flash Point 377.3±32.9 °C
Vapour Pressure 0.0±2.3 mmHg at 25°C
Index of Refraction 1.682
LogP 7.31
Hydrogen Bond Donor Count 2
Hydrogen Bond Acceptor Count 4
Rotatable Bond Count 5
Heavy Atom Count 32
Complexity 664
Defined Atom Stereocenter Count 0
SMILES

C1CCC2=C(C1)C(=C(S2)/N=C/C3=C(C=CC4=CC=CC=C43)O)C(=O)NCC5=CC=CC=C5

InChi Key CRTIXRJWHKMWCH-STBIYBPSSA-N
InChi Code

InChI=1S/C27H24N2O2S/c30-23-15-14-19-10-4-5-11-20(19)22(23)17-29-27-25(21-12-6-7-13-24(21)32-27)26(31)28-16-18-8-2-1-3-9-18/h1-5,8-11,14-15,17,30H,6-7,12-13,16H2,(H,28,31)/b29-17+
Chemical Name

N-benzyl-2-[(E)-(2-hydroxynaphthalen-1-yl)methylideneamino]-4,5,6,7-tetrahydro-1-benzothiophene-3-carboxamide
Synonyms

JGB1741; ILS-JGB-1741
HS Tariff Code 2934.99.9001
Storage

Powder-20°C 3 years

4°C 2 years

In solvent -80°C 6 months

-20°C 1 month

Note: This product requires protection from light (avoid light exposure) during transportation and storage.
Shipping Condition Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)

Biological Activity


Targets SIRT1 ( IC50 ~ 15 μM ); SIRT2 ( IC50 > 100 μM ); SIRT3 ( IC50 > 100 μM )
ln Vitro JGB1741 (ILS-JGB-1741; 1-10000 nM; 24 h) suppresses the growth of MDA-MB 231 cells[1].
JGB1741 (0.01-1 μM; 24 h) causes MDA-MB 231 cells to undergo apoptosis[1].
JGB1741 (0.01-1 μM; 24 h) exhibits a G1 phase cell cycle arrest, with an increasing number of cells transitioning into the sub G0/G1 phase[1].
JGB1741 (0.01-1 μM; 24 h) exhibits elevated levels of acetylated p53K382, p53 expression, and global acetylation of H3K9[1].
Cell Assay Cell Line: K562, HepG2 and MDA-MB 231 cell lines
Concentration: 1, 10, 50, 100, 500, 1000, 10000 nM
Incubation Time: 24 hours
Result: Inhibited MDA-MB 231 cell proliferation more potently with an IC50 of 0.5 μM than K562 and HepG2 cell proliferation (IC50>1 μM).
References

[1]. Inhibition of SIRT1 by a small molecule induces apoptosis in breast cancer cells. Biochem Biophys Res Commun. 2010 Oct 8;401(1):13-9.


Solubility Data


Solubility (In Vitro) DMSO : ~5 mg/mL (~11.4 mM)
Solubility (In Vivo) Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.

Injection Formulations
(e.g. IP/IV/IM/SC)
Injection Formulation 1: DMSO : Tween 80: Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution 50 μL Tween 80 850 μL Saline)
*Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution.
Injection Formulation 2: DMSO : PEG300 :Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO 400 μLPEG300 50 μL Tween 80 450 μL Saline)
Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO 900 μL Corn oil)
Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals).
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO 900 μL (20% SBE-β-CD in saline)]
*Preparation of 20% SBE-β-CD in Saline (4°C,1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution.
Injection Formulation 5: 2-Hydroxypropyl-β-cyclodextrin : Saline = 50 : 50 (i.e. 500 μL 2-Hydroxypropyl-β-cyclodextrin 500 μL Saline)
Injection Formulation 6: DMSO : PEG300 : castor oil : Saline = 5 : 10 : 20 : 65 (i.e. 50 μL DMSO 100 μLPEG300 200 μL castor oil 650 μL Saline)
Injection Formulation 7: Ethanol : Cremophor : Saline = 10: 10 : 80 (i.e. 100 μL Ethanol 100 μL Cremophor 800 μL Saline)
Injection Formulation 8: Dissolve in Cremophor/Ethanol (50 : 50), then diluted by Saline
Injection Formulation 9: EtOH : Corn oil = 10 : 90 (i.e. 100 μL EtOH 900 μL Corn oil)
Injection Formulation 10: EtOH : PEG300:Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL EtOH 400 μLPEG300 50 μL Tween 80 450 μL Saline)

Oral Formulations Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium)
Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose
Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals).
Oral Formulation 3: Dissolved in PEG400
Oral Formulation 4: Suspend in 0.2% Carboxymethyl cellulose
Oral Formulation 5: Dissolve in 0.25% Tween 80 and 0.5% Carboxymethyl cellulose
Oral Formulation 6: Mixing with food powders

Note: Please be aware that the above formulations are for reference only. InvivoChem strongly recommends customers to read literature methods/protocols carefully before determining which formulation you should use for in vivo studies, as different compounds have different solubility properties and have to be formulated differently.

 (Please use freshly prepared in vivo formulations for optimal results.)
Preparing Stock Solutions 1 mg 5 mg 10 mg
1 mM 2.2698 mL 11.3492 mL 22.6984 mL
5 mM 0.4540 mL 2.2698 mL 4.5397 mL
10 mM 0.2270 mL 1.1349 mL 2.2698 mL
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.